InSightec's ExAblate Neuro System Awarded European CE Mark for Non-invasive
Treatment of Neurological Disorders in the Brain
TIRAT CARMEL, Israel, December 4, 2012
TIRAT CARMEL, Israel, December 4, 2012 /PRNewswire/ --
ExAblate treatment is indicated for use for essential tremor, tremor dominant
Parkinson's disease and neuropathic pain
InSightec Ltd. announced that its transcranial focused ultrasound system,
ExAblate Neuro, has been awarded the European CE mark for the treatment of
neurological disorders in the brain including essential tremor, Parkinson's
disease and neuropathic pain.
Millions of people suffer from neurological disorders which cause significant
disability and negatively affect their quality of life and that of their
caretakers. Treatment options for patients who do not respond to drug
treatments include deep brain stimulation, radiofrequency ablation and
radiosurgery which are invasive or involve ionizing radiation and are
associated with recognized risks: high doses of ionizing radiation or high
risk of complications and side effects including infection, bleeding and
collateral brain tissue damage.
"ExAblate offers great potential for treating brain disorders. Because of its
targeting accuracy, real time treatment monitoring and ability to provide non-
invasive brain treatment, there is hope that many people who suffer from
neurological diseases can benefit from this treatment," said Dr. Kobi Vortman,
President of InSightec. "Results from the clinical studies showed that
patients, many of whom who suffered for years from neurological disorders,
experienced immediate symptom improvement with a high safety profile. These
patients are now better able to conduct activities of daily living and are
also less dependent on external caregiver support."
"ExAblate® Neuro offers a non-invasive treatment with no ionizing radiation,
which treats tissue deep in the brain through an intact skull. MR guided
Focused ultrasound (MRgFUS) combines therapeutic acoustic ultrasound waves
with continuous MRI guidance," added Eyal Zadicario, Vice President of R&D and
Director of InSightec's Neuro program. "The MRI enables physicians to
visualize, plan, guide, monitor and control the treatment while the ultrasound
acoustic energy destroys the targeted tissue in the brain."
InSightec recently received its second ExAblate FDA approval for the treatment
of painful bone metastases in patients who are unable or unwilling to undergo
radiation. This is in addition to FDA approval for the treatment of uterine
fibroids received in 2004. The CE marking enables ExAblate Neuro to be sold in
InSightec Ltd. is privately held by Elbit Imaging, General Electric, and
MediTech Advisors. Founded in 1999 InSightec developed ExAblate to transform
MRI-guided Focused Ultrasound (MRgFUS) into a clinically viable technology.
ExAblate has won several awards for innovation and its potential to help
mankind including The Wall Street Journal Technology Innovation Awards and the
European Union's IST grand prize. TIME magazine recently named Focused
Ultrasound as "one of 50 best inventions". For more information about
treatment centers and brain disorders please visit: http://www.insightec.com .
SOURCE InSightec Ltd
Press spacebar to pause and continue. Press esc to stop.